Table 8.
Associations between performance in the RAVL (trials no. 1–10) and cardio-metabolic risk markers after the active diet, obtained with regression analyses (model 1 and model 2) 1
|
RAVLT, active diet | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean trial no. 1–5 (n = 42) | Trial no. 6 (n = 40) | Trial no. 7 (n = 41) | Trial no. 8 (n = 41) | Trial no. 9 (n = 41) | Trial no. 10 (n = 39) | |||||||||||||
| MODEL 1. |
R2: 0.32 |
R2: 0.31 |
R2: 0.30 |
R2: 0.30 |
R2: 0.24 |
R2: 0.17 |
||||||||||||
| Adj- R2: 0.22 |
Adj- R2: 0.21 |
Adj- R2: 0.21 |
Adj- R2: 0.20 |
Adj- R2: 0.14 |
Adj- R2: 0.04 |
|||||||||||||
| P < 0.05 |
P < 0.05 |
P < 0.05 |
P < 0.05 |
P = 0.07 |
P = 0.29 |
|||||||||||||
| MODEL 2. |
coef |
(std Err) |
beta |
coef |
(std Err) |
beta |
coef |
(std Err) |
beta |
coef |
(std Err) |
beta |
coef |
(std Err) |
beta |
coef |
(std Err) |
beta |
| Total- cholesterol |
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
| ApoA1 |
7.5* |
(3.1) |
0.32 |
- |
|
|
9.6* |
(3.8) |
0.34 |
445** |
(157) |
0.30 |
- |
|
|
7.9* |
(3.3) |
0.36 |
| Systolic BP2 |
−0.10** |
(0.04) |
−0.40 |
- |
|
|
−0.11* |
(0.04) |
−0.37 |
−3.9* |
(1.7) |
−0.31 |
- |
|
|
- |
|
|
| Glucose |
- |
|
|
−0.44* |
(0.28) |
−0.37 |
- |
|
|
- |
|
|
−3576* |
(1449) |
−0.36 |
- |
|
|
| Const. | 21.6 | (6.6) | 5.4 | (0.98) | 22.5 | (8.0) | 382 | (327) | 42288 | (7930) | 6.0 | (4.7) | ||||||
*: p < 0.05, **: p < 0.01. n = 43.
1 Cardio-metabolic risk markers included in model 1 are: systolic blood pressure, fasting concentrations of total cholesterol, Apo A-1, insulin, and glucose. Model 2 includes test variables revealing significant effects on cognitive performance after step-wise, one-by-one elimination of non-significant test markers in model 1. 2BP blood pressure.